151 related articles for article (PubMed ID: 32393597)
1. Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.
Littlejohn E
Cleve Clin J Med; 2020 May; ():. PubMed ID: 32393597
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
3. Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
Wakiya R; Ueeda K; Shimada H; Nakashima S; Kameda T; Miyatake N; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
Clin Rheumatol; 2022 Nov; 41(11):3345-3353. PubMed ID: 35849246
[TBL] [Abstract][Full Text] [Related]
4. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
Takamasu E; Yokogawa N; Shimada K; Sugii S
Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C; Moroni G
Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
[TBL] [Abstract][Full Text] [Related]
6. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
[TBL] [Abstract][Full Text] [Related]
7. The presumable effects of hydroxychloroquine and its metabolites in the treatment of systemic lupus erythematosus.
Pan M; Jin R; Dai Y; Gao B; Liu Y; Peng X; Qiao J; Shuai Z
Int Immunopharmacol; 2024 Jan; 126():111269. PubMed ID: 38006753
[TBL] [Abstract][Full Text] [Related]
8. Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus.
Abdelbaky MSE; El Mamoun TA; Mabrouk FI; Hassan RM
Egypt J Intern Med; 2021; 33(1):18. PubMed ID: 34121836
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita S; Takahashi T; Yoshida Y; Yokota N
Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
[TBL] [Abstract][Full Text] [Related]
10. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
[TBL] [Abstract][Full Text] [Related]
12. Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
Lee SG; Park EK; Park JH; Kweon SM; Kim YK; Kim GT
Lupus; 2018 Apr; 27(5):753-761. PubMed ID: 29157178
[TBL] [Abstract][Full Text] [Related]
13. Rheumatologists' perspective on hydroxychloroquine guidelines.
Winebrake J; Khalili L; Weiner J; Gartshteyn Y; Park L; Askanase AD
Lupus Sci Med; 2020 Nov; 7(1):. PubMed ID: 33148665
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
Yang J; Yang X; Yang J; Li M
J Rheumatol; 2018 Jun; 45(6):818-826. PubMed ID: 29545450
[TBL] [Abstract][Full Text] [Related]
15. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Hosokawa Y; Oiwa H
Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
[TBL] [Abstract][Full Text] [Related]
16. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
18. Update on antimalarials and systemic lupus erythematosus.
Ruiz-Irastorza G; Martín-Iglesias D; Soto-Peleteiro A
Curr Opin Rheumatol; 2020 Nov; 32(6):572-582. PubMed ID: 32890029
[TBL] [Abstract][Full Text] [Related]
19. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.
Husayn SS; Brown JD; Presley CL; Boghean K; Waller JD
J Pharm Pract; 2022 Feb; 35(1):120-125. PubMed ID: 32734810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
